Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$14.51 - $20.99 $43 - $62
-3 Reduced 0.03%
11,866 $172,000
Q3 2022

Nov 09, 2022

SELL
$18.21 - $27.88 $3,896 - $5,966
-214 Reduced 1.77%
11,869 $226,000
Q2 2022

Aug 10, 2022

BUY
$16.45 - $25.88 $3,520 - $5,538
214 Added 1.8%
12,083 $220,000
Q1 2022

May 13, 2022

SELL
$22.67 - $28.01 $5,667 - $7,002
-250 Reduced 2.06%
11,869 $299,000
Q4 2021

Feb 14, 2022

SELL
$24.13 - $32.63 $1.21 Million - $1.63 Million
-50,000 Reduced 80.49%
12,119 $334,000
Q3 2021

Nov 12, 2021

BUY
$29.97 - $36.66 $1.5 Million - $1.83 Million
50,000 Added 412.58%
62,119 $2.01 Million
Q4 2020

Feb 09, 2021

SELL
$12.16 - $19.77 $39,848 - $64,786
-3,277 Reduced 21.28%
12,119 $240,000
Q3 2020

Nov 06, 2020

SELL
$11.25 - $14.75 $708 - $929
-63 Reduced 0.41%
15,396 $201,000
Q2 2020

Aug 12, 2020

SELL
$10.69 - $16.49 $17,296 - $26,680
-1,618 Reduced 9.47%
15,459 $175,000
Q1 2020

May 11, 2020

BUY
$9.78 - $29.53 $18,445 - $55,693
1,886 Added 12.42%
17,077 $244,000
Q2 2019

Aug 13, 2019

SELL
$22.67 - $35.0 $6,098 - $9,415
-269 Reduced 1.74%
15,191 $458,000
Q1 2019

May 14, 2019

SELL
$26.93 - $34.7 $14,219 - $18,321
-528 Reduced 3.3%
15,460 $513,000
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $29,953 - $50,116
-1,100 Reduced 6.44%
15,988 $482,000
Q3 2018

Nov 13, 2018

BUY
$37.57 - $50.34 $71,383 - $95,646
1,900 Added 12.51%
17,088 $786,000
Q4 2017

Feb 14, 2018

SELL
$28.45 - $37.14 $1.01 Million - $1.32 Million
-35,560 Reduced 70.07%
15,188 $522,000
Q3 2017

Nov 13, 2017

BUY
$24.01 - $36.2 $1.22 Million - $1.84 Million
50,748
50,748 $1.84 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.09B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.